Sign In
Buy IMGN
$31.23
+0 (+0%)
At Close: May 08, 2024
Should You Buy ImmunoGen (IMGN) Ahead of Earnings?
10:35am, Thursday, 03'rd Nov 2022
ImmunoGen (IMGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?
06:21pm, Tuesday, 01'st Nov 2022 Zacks Investment Research
Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.
Zoetis (ZTS) to Report Q3 Earnings: Is a Beat in Store?
05:09pm, Monday, 31'st Oct 2022 Zacks Investment Research
Zoetis (ZTS) is anticipated to report positive earnings and revenues for third-quarter 2022. It will also provide an update on its pipeline on the earnings call.
ImmunoGen (IMGN) Expected to Beat Earnings Estimates: Should You Buy?
02:00pm, Friday, 28'th Oct 2022 Zacks Investment Research
ImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ImmunoGen Before The PDUFA
07:00am, Thursday, 27'th Oct 2022
ImmunoGen has a PDUFA on November 28. The NDA is based on data from the Soraya trial.
Agenus (AGEN) to Report Q3 Earnings: What's in the Cards?
02:11pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
On Agenus' (AGEN) third-quarter earnings call, investor focus is likely to be on the company's progress with the developments of its pipeline candidates.
Novavax (NVAX) to Report Q3 Earnings: What's in the Cards?
11:07am, Monday, 24'th Oct 2022 Zacks Investment Research
On Novavax's (NVAX) third-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2022 Operating Results
04:01pm, Thursday, 20'th Oct 2022
WALTHAM, Mass.
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference
04:30pm, Wednesday, 14'th Sep 2022
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
02:40pm, Friday, 09'th Sep 2022 Benzinga
Upgrades
For 3M Co (NYSE:MMM), UBS upgraded the previous rating of Sell to Neutral. For the second quarter, 3M had an EPS of $2.48, compared to year-ago quarter EPS of $2.59. The current stock perform
Why Is Pacira (PCRX) Down 9.2% Since Last Earnings Report?
03:31pm, Friday, 02'nd Sep 2022 Zacks Investment Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunogen (IMGN) Provides Preliminary Data on Rare Blood Cancer Candidate
04:42pm, Thursday, 01'st Sep 2022 Zacks Investment Research
Immunogen (IMGN) announces preliminary data on its CADENZA study evaluating pivekimab in blastic plasmacytoid dendritic cell neoplasm.
Esperion Therapeutics (ESPR) Up 29.3% Since Last Earnings Report: Can It Continue?
03:31pm, Thursday, 01'st Sep 2022 Zacks Investment Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunogen (IMGN) Provides Preliminary Data on Rare Blood Cancer Candidate
01:53pm, Thursday, 01'st Sep 2022
Immunogen (IMGN) announces preliminary data on its CADENZA study evaluating pivekimab in blastic plasmacytoid dendritic cell neoplasm.
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates
03:13pm, Monday, 01'st Aug 2022 Zacks Investment Research
ImmunoGen (IMGN) reports a wider-than-expected loss for second-quarter 2022. It also misses revenue estimates.
